Recombinant Microorganism for Heme Production via HemA and DtxR
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing 5-aminolevulinic acid, a precursor to heme and porphyrin analogues, are costly and inefficient, limiting the production of heme, coproporphyrin III, and uroporphyrin III.
Innovation Solution
A recombinant microorganism is developed by introducing genes encoding glutamyl-tRNA reductase (HemA), glutamate-1-semialdehyde aminotransferase (HemL), and diphtheria toxin repressor (DtxR) into a strain overproducing L-glutamic acid, enabling high-yield production of heme, coproporphyrin III, and uroporphyrin III through optimized gene expression and iron ion activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce 5-aminolevulinic acid, then production cost is reduced, but production efficiency and yield are insufficient
Solution Approach 1:
The patent modifies the metabolic parameters of the microorganism by introducing and overexpressing specific genes (hemA, hemL, dtxR) that encode enzymes and transcription factors involved in the C5 pathway of 5-aminolevulinic acid synthesis. This changes the biochemical parameters of the host strain to enhance production efficiency while maintaining cost-effectiveness through genetic modification rather than complex process changes
2Productivity
If the C5 pathway is used for heme synthesis, then production of heme and porphyrin analogues is enabled, but the pathway is less efficient compared to the C4 pathway
Solution Approach 1:
The patent performs preliminary action by introducing the dtxR transcription factor that activates the expression of hemA and hemL genes before the actual synthesis occurs. This pre-preparation of enzymatic machinery ensures that when the C5 pathway operates, it does so with high efficiency, overcoming the inherent inefficiency of the pathway through proactive genetic engineering
Solution Approach 2:
The patent ensures continuous useful action by creating a strain where the C5 pathway enzymes are constitutively expressed at high levels. The overexpression of hemA, hemL, and activation of dtxR maintain continuous flux through the pathway, eliminating bottlenecks and ensuring steady production of heme and porphyrin analogues without interruption
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant microorganism significantly enhances the production yields of heme, coproporphyrin III, and uroporphyrin III, outperforming conventional strains and providing a more economical method for these valuable compounds.
Implementation Method 1
a gene encoding a glutamyl-tRNA reductase (HemA), a gene encoding a glutamate-1-semialdehyde aminotransferase (HemL)... to produce 5-aminolevulinic acid (ALA), which is a precursor of heme
Implementation Method 2
a gene encoding a diphtheria toxin repressor (DtxR), which is a transcription factor capable of inducing the expression of genes related to heme metabolic pathways
Implementation Method 3
the synthesis of heme is completed through integration of iron ions (ferrous ions) into protoporphyrin IX (Proto IX) by ferrochelatase (HemH)
Data Source
AI summary
The present invention relates to a recombinant microorganism having an enhanced ability to produce heme, coproporphyrin III (Copro III), and uroporphyrin III (Uro III), and a method for producing heme, coproporphyrin III, and uroporphyrin III using same. When using a recombinant microorganism incorporating a gene that codes glutamyl-tRNA reductase (HemA), glutamate-1-semialdehyde aminotransferase (HemL), and diphtheria toxin repressor (DtxR), which is a transcription factor capable of inducing the expression of genes related to heme metabolic pathways, porphyrin-based structures can be produced at high yield, and thus the method is economic.